These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
535 related articles for article (PubMed ID: 28925899)
21. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer. Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549 [TBL] [Abstract][Full Text] [Related]
23. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279 [TBL] [Abstract][Full Text] [Related]
24. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116 [TBL] [Abstract][Full Text] [Related]
26. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490 [TBL] [Abstract][Full Text] [Related]
28. Management of bone loss in men with prostate cancer. Higano CS J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412 [TBL] [Abstract][Full Text] [Related]
29. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Conteduca V; Di Lorenzo G; Tartarone A; Aieta M Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636 [TBL] [Abstract][Full Text] [Related]
30. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer]. Kudlacek S; Puntus T Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632 [TBL] [Abstract][Full Text] [Related]
31. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Clinton TN; Woldu SL; Raj GV Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768 [TBL] [Abstract][Full Text] [Related]
32. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142 [TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915 [TBL] [Abstract][Full Text] [Related]
35. Fracture risk in patients with prostate cancer on androgen deprivation therapy. López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259 [TBL] [Abstract][Full Text] [Related]
36. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Greiman AK; Keane TE Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429 [TBL] [Abstract][Full Text] [Related]
37. Effect of androgen suppression on bone mineral density in patients with prostate cancer. Chernichenko OA; Sakalo VS; Yakovlev PG; Sakalo AV; Zhylchuk YV; Zsolt A Exp Oncol; 2014 Dec; 36(4):276-8. PubMed ID: 25537224 [TBL] [Abstract][Full Text] [Related]
38. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Daniell HW Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461 [TBL] [Abstract][Full Text] [Related]
39. Quality of life in prostate cancer patients taking androgen deprivation therapy. Dacal K; Sereika SM; Greenspan SL J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202 [TBL] [Abstract][Full Text] [Related]
40. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]